TQB2928 / Sino Biopharm - LARVOL DELTA

TQB2928-ALTN-Ib-01: TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors (clinicaltrials.gov) - P1 | N=20 | Terminated | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | N=43 ➔ 20 | Trial completion date: Feb 2026 ➔ Jun 2025 | Recruiting ➔ Terminated | Trial primary completion date: Oct 2025 ➔ Jun 2025; This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

TQB2928, A NOVEL ANTI-CD47 MONOCLONAL ANTIBODY, IN COMBINATION WITH ANLOTINIB FOR THE TREATMENT OF RECURRENT/METASTATIC OSTEOSARCOMA: A PHASE 1B STUDY (CTOS 2025) - No abstract available

Combination therapy • Metastases • P1 data • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Combination therapy • Metastases • New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors. (clinicaltrials.gov) - P1 | N=3 | Terminated | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=114 ➔ 3 | Trial completion date: Mar 2028 ➔ Jul 2024 | Recruiting ➔ Terminated | Trial primary completion date: Jun 2026 ➔ Jul 2024; Based on the current status of the same target research and the company's overall layout in the field of tumors, the early termination was determined after full communication with the principal investigator of the group leader unit.

Enrollment change • Metastases • Trial completion date • Trial primary completion date • Trial termination • Lymphoma • Oncology • Solid Tumor

TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors. (clinicaltrials.gov) - P1 | N=114 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Lymphoma • Oncology • Solid Tumor

TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors (clinicaltrials.gov) - P1 | N=43 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Metastases • New P1 trial • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors. (clinicaltrials.gov) - P1 | N=114 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor

Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Combination therapy • New P1 trial • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

Clinical Trial of the TQB2928 Injection in Patients With Advanced Cancers (clinicaltrials.gov) - P1 | N=180 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Oncology • Solid Tumor

Clinical Trial of the TQB2928 Injection in Patients With Advanced Cancers (clinicaltrials.gov) - P1; N=180; Not yet recruiting; Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Clinical • New P1 trial • Hematological Malignancies • Oncology • Solid Tumor

Phase 1 Trial of the TQB2928 Injection in Patients With Advanced Cancers (clinicaltrials.gov) - P1; N=20; Not yet recruiting; Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Clinical • New P1 trial • Hematological Disorders • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor